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The same patients provided the cost data and the effectiveness data. However, headache-related visits were available for only 250 patients. It was unclear whether the costing was conducted retrospectively or prospectively.
Study sample
No power calculations to determine the sample size were reported. All 264 patients attending the headache clinic classes between April 1999 and April 2000 were included in the study.
Study design
This was a case-series study that was conducted in a single centre. The duration of follow-up was 6 months before the intervention and 6 months after. No loss to follow-up was reported.
Analysis of effectiveness
The basis of the analysis was intention to treat. The primary health outcome was the frequency of severe headaches, using a Brief Headache Screen.
Effectiveness results
At baseline, 91 patients reported severe headaches more than 2 days a week. Six months later, 72 (73%) of the 91 patients provided follow-up data. Of those 72 patients, 62 (86%) reported fewer severe headaches. Fifty-five patients (76%) reported severe headaches 2 days per week or less. Twenty-seven patients (37.5%) patients had severe headaches once a month or less.
Clinical conclusions
The results on headache severity showed an improvement in health.
Measure of benefits used in the economic analysis
No summary measure of benefit was used. In effect, a cost-consequences analysis was carried out.
Direct costs
The perspective adopted was unclear. Discounting was not carried out as the costs were incurred during less than 2 years. The costs measured were for clinic visits, ED visits and pharmacy. The pharmacy costs were restricted to the costs of triptans (sumatriptan, rizatriptan, naratriptan and zolmitriptan) and dihydroergotamine. The cost of parenteral triptans administered during clinic visits was not included. The costs were estimated from actual data. The headacherelated visits were reviewed for 250 patients, while the pharmacy costs were reviewed for 264 patients. The number of visits was taken from the study, while the authors chose a theoretical cost of the visits. The source of the drug prices was not given. Uniform unit costs per dose were assigned to triptans and dihydroergotamine. The clinic and ED visits were broken down into prices and quantities, while the drug costs were given as the total costs and prices. No price year was given.
Statistical analysis of costs
No statistical analysis of the costs was carried out. costs were estimated. It would have been more appropriate to have included the indirect costs of the health technology, as headaches can often result in time taken off work. The cost of parenteral triptans administered during clinic visits and the costs of the educational programme were not included. The authors reported that hospitalisation was rarely required, but they did not state precisely how many patients required hospitalisation during the follow-up period. The costs and the quantities were only reported separately for clinic and ED visits. No statistical or other analyses of the quantities were conducted. The authors did not explain how (authors' setting or authors' opinion) they arrived at the price of clinic and ED visits and medication. No statistical or sensitivity analyses of the prices were performed. The date to which the prices related was not reported, but it could be assumed that the date lay within the dates of the effectiveness data (i.e. 1998 -2000) .
Other issues
The authors compared their work with another study (see Other Publication of Related Interest). The issue of generalisability was addressed. Any comparison with other work would have to ensure that the same study population was being studied. The authors were aware that the kind of health plan used will affect the results. The authors did report limitations of their study (highlighted in other sections of the commentary). The fact that the unit costs were estimated from the authors' setting or authors' opinions does not enhance the external validity of the analysis.
Implications of the study
For the authors, this study demonstrated that "principles of disease management can be effectively applied to a headache population, with a positive financial impact on a managed care organisation". However, due to the weaknesses of the study, further research is required to enhance the validity of the conclusions.
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